166 related articles for article (PubMed ID: 32867107)
1. Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma-A Cost-Effectiveness Analysis.
Schnitzer ML; Froelich MF; Gassert FG; Huber T; Gresser E; Schwarze V; Nörenberg D; Todica A; Rübenthaler J
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867107
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET/CT for detecting colorectal liver metastases eligible for hepatic resection.
Schnitzer ML; von Münchhausen N; Biechele G; Runtemund J; Grawe F; Geyer T; Kaiser CG; Haag F; Rübenthaler J; Froelich MF
Front Oncol; 2023; 13():1161738. PubMed ID: 37554160
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
5.
Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of
Froelich MF; Schnitzer ML; Holzgreve A; Gassert FG; Gresser E; Overhoff D; Schwarze V; Fabritius MP; Nörenberg D; von Münchhausen N; Hokamp NG; Auernhammer CJ; Ilhan H; Todica A; Rübenthaler J
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33670457
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
[TBL] [Abstract][Full Text] [Related]
10. Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis.
Gassert FG; Ziegelmayer S; Luitjens J; Gassert FT; Tollens F; Rink J; Makowski MR; Rübenthaler J; Froelich MF
Eur Radiol; 2022 Apr; 32(4):2448-2456. PubMed ID: 34837511
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
12. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
[TBL] [Abstract][Full Text] [Related]
13. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
14. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
15. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
de Koster EJ; Vriens D; van Aken MO; Dijkhorst-Oei LT; Oyen WJG; Peeters RP; Schepers A; de Geus-Oei LF; van den Hout WB;
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3452-3469. PubMed ID: 35435497
[TBL] [Abstract][Full Text] [Related]
16. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
17. Supplemental
Bicu F; Rink JS; Froelich MF; Cyran CC; Rübenthaler J; Birgin E; Röhrich M; Tollens F
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803522
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer.
Froelich MF; Schnitzer ML; Rathmann N; Tollens F; Unterrainer M; Rennebaum S; Seidensticker M; Ricke J; Rübenthaler J; Kunz WG
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806059
[TBL] [Abstract][Full Text] [Related]
19. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.
Lo AC; James LP; Prica A; Raymakers A; Peacock S; Qu M; Louie AV; Savage KJ; Sehn LH; Hodgson D; Yang JC; Eich HTT; Wirth A; Hunink MGM
J Nucl Med; 2022 Apr; 63(4):543-548. PubMed ID: 34413148
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
